Lookup NU author(s): Professor Penny Lovat,
Professor Archibald Malcolm,
Professor Andrew Pearson,
Dr Chris Redfern
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
To date, the clinical success of 13-cis or all-trans retinoic acid in the treatment of neuroblastoma has been disappointing. In vivo, 13-cis will isomerise to both all-trans and 9-cis retinoic acid, believed to be the main biologically-active isomers. In vitro studies with an N-type neuroblastoma cell line, SH SY 5Y, show that 9-cis is better than other isomers at both inducing morphological differentiation and inhibiting proliferation. RAR-β, a gene which may mediate retinoic acid responsiveness and be of prognostic significance, is also more-effectively induced by 9-cis retinoic acid. 9-cis and all-trans retinoic acid do not have synergistic effects on SH SY 5Y cell proliferation and gene expression. A retinoid X receptor (RXR)-specific analogue of 9-cis retinoic acid had similar effects on gene expression to 9-cis retinoic acid alone. In view of these results, 9-cis retinoic acid or stable analogues of this retinoid may have potential for the treatment of neuroblastoma.
Author(s): Lovat, P.E., Irving, H., Malcolm, A.J., Pearson, A.D.J., Redfern, C.P.F.
Publication type: Article
Publication status: Published
Journal: Journal of Neuro-Oncology
Print publication date: 01/01/1997
ISSN (print): 0167-594X
ISSN (electronic): 1573-7373
PubMed id: 9049833
Altmetrics provided by Altmetric